Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz

{
  "signal_id": "05e2384d-a1b9-7c9a-1d2a-614c48510fac",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-26T00:23:37+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-incyte-announce-fda-approval-of-atebrioz-thefly-news",
    "title": "Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz - TipRanks",
    "excerpt": "Mirum Pharmaceuticals ( MIRM ) and Incyte ( INCY ) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The recommended dose of Atebrioz is 100 mg administered orally, once daily. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on MIRM: Disclaimer & Disclosure Report an Issue",
    "product": "Atebrioz",
    "summary": "Incyte, in collaboration with Mirum Pharmaceuticals, received FDA approval for its Atebrioz tablets, a treatment for fibrodysplasia ossificans progressiva in patients aged 12 and older.",
    "location": "United States",
    "planning": false,
    "image_url": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1917115745-750x406.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "Atebrioz",
      "full_text": "Atebrioz tablets",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-26T00:23:37Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Mirum Pharmaceuticals ( MIRM ) and Incyte ( INCY ) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva.",
    "related_company_name": "Mirum Pharmaceuticals",
    "related_company_domain": "mirumpharma.com"
  }
}

curl https://signals.autobound.ai/v1/signals/05e2384d-a1b9-7c9a-1d2a-614c48510fac \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'